Is Ovid Therapeutics Inc (OVID) overvalued? · rev $733.0K
Ovid Therapeutics Inc (OVID) is a biotechnology company listed on US.
This page asks whether Ovid Therapeutics Inc (OVID) looks expensive on cached numbers — not a short thesis.
Latest reported OVID revenue for 2026-06-30 was $733.0K. Net income was -$32.0M. OVID currently screens at market cap $23.5M.
OVID currently screens at market cap $23.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next OVID 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the OVID stock page for the full model, not this heading.
Not investment advice.